The approval has been held up by one member of the FDA, even though Cerus hit the primary endpoints in its pivotal Phase III trial and is receiving grants from the Department of Defense. FDA는 더 이상 시간을 끌지 말아야 합니다. There is no scientific or product risk in this stock.